


Terumo takes over WuXi Biologics' drug product plant in Germany for EUR 150 million

May 15, 2025 | News

WuXi Biologics enters into an agreement with Terumo on Leverkusen drug product plant



China-based WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has entered into an agreement with Terumo Corporation that Terumo will take over WuXi Biologics' drug product (DP) plant in Leverkusen, Germany for EUR 150 million. The transaction is expected to be concluded in 2025, subject to the satisfaction of customary closing conditions.

Divesting the Leverkusen facility is a strategic step in aligning with the company's long-term growth to enhance agility, scale diversified solutions for its global clients, and address emerging needs worldwide. This decision will allow WuXi Biologics to exclusively focus on building large-scale global DP manufacturing capacities in Singapore while optimising returns on assets for future growth.

As a result, WuXi Biologics has completed the strategic review of all sites and will focus on building and developing its current sites.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).